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Ewan R. Pearson
Dissecting the Etiology of Type 2 Diabetes
in the Pima Indian Population
Diabetes 2015;64:3993–3995 | DOI: 10.2337/dbi15-0016
The Pima Indian population of Arizona has one of the
highest prevalence of diabetes of any population in the
world, and the Pima Indians of the Gila River Indian
Community have probably been the most studied group
for the causes and consequences of diabetes. They develop
what would be considered to be classic type 2 diabetes,
characterized by obesity and insulin resistance with pro-
gression to diabetes characterized by progressive b-cell
dysfunction (1).
Given the low degree of admixture and high heritability
of type 2 diabetes in the Pima Indians (2), the population
should also represent a honeypot for genetic discovery.
While in recent years there has been progress in identi-
fying type 2 diabetes risk variants in this population (3,4),
the understanding of the genetic contribution to diabetes
risk remains far from complete. Like many initiatives in
genetics, whole-genome/exome sequencing is now being
applied in the hope that rare/low-frequency variants with
large effects on diabetes risk will be found.
In this issue of Diabetes, Baier et al. (5) report on the
results of a targeted sequencing project focusing on the
genes encoding the two subunits of the b-cell KATP channel.
Variants identiﬁed by whole-genome sequencing in ABCC8
and KCNJ11 in 335 Pima Indians are genotyped in 7,710
individuals of full Pima Indian heritage or mixed American
Indian heritage (;4/8th Pima Indian). They identify an
R1420H variant present in 3.3% of the population that
is associated with a doubling of the risk for type 2 diabetes,
with diabetes developing, on average, 7 years earlier in
those heterozygous for the variant. Baier et al. show that
this variant, which appears to be private to the Pima Indian
population, is functionally inactivating, similar to the
R1420C mutation that is known to cause hyperinsuline-
mic hypoglycemia of infancy. In keeping with this, they
report the R1420H variant is associated with a 170-g
increase in birth weight consistent with fetal hyperinsu-
linemia (Fig. 1). Thus, in a beautiful parallel of the mono-
genic disease, the diabetes risk variant is associated with
increased insulin secretion in utero but decreased b-cell
function in adult life (6). This scenario of hyperinsulinism
in utero followed by early failure of b-cell function is also
described in maturity-onset diabetes of the young owing to
HNF4A mutations (7), and the mechanism for this switch
from over- to undersecretion remains poorly understood.
In addition to reporting the association of the ABCC8
1420H variant with increased diabetes risk and increased
birth weight, Baier et al. (5) also report that this variant is
associated with low adult BMI (Fig. 1). To avoid confounding
that could occur in a cross-sectional analysis, whereby
those genetically at risk for diabetes develop diabetes at a
younger age and lower BMI, the authors use the compre-
hensive longitudinal data available to establish that this
effect is seen consistently over time in both those who
develop diabetes and those who do not. This result certainly
suggests a role for variation in ABCC8 function outside of
the pancreatic b-cell. KATP channels are present in the
hypothalamus, where they are involved in glucose sensing
and appetite regulation. While, to my knowledge, patients
with congenital hyperinsulinism are not reported to have
low BMI in adulthood, there are two mouse models that
support this ﬁnding. In one model, Kir6.2 knockout mice
that were fed a high-fat diet were resistant to weight gain
(8). In a second model, activation of KATP speciﬁcally in
proopiomelanocortin neurons drove hyperphagia and an
obese phenotype in mice (9). It would be certainly interesting,
if challenging, to investigate appetite and leptin regulation in
the Pima Indian subgroup with the 1420H variant.
Baier et al. (5) highlight how the carrier frequency for
this inactivating ABCC8 variant will result in a clinically
important risk of homozygous infants with severe hyper-
insulinism. While this is undoubtedly true and raises the
possibility of prepregnancy genetic testing, the ﬁnding of this
variant present at 3% that has a clear impact on diabetes
phenotype has an important implication for our under-
standing of “type 2 diabetes.” There is a tendency to think
of type 2 diabetes as one disease characterized by obesity
and insulin resistance, as is typically seen in the Pima
Indians. Yet, now we can begin to see how genetics can
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unravel the pathophysiology of diabetes, identifying sub-
groups of distinct etiology, even in this population with
classic type 2 diabetes. The key step that is required is to
establish the clinical utility of this ﬁnding in this genetically
deﬁned subgroup. The mouse models of hyperinsulinism
have reduced b-cell insulin content and poor response to
incretin stimulation (10,11). It would be interesting to see
how this genetically deﬁned subgroup would respond
to sulfonylureas, dipeptidyl peptidase-4 inhibitors, and
glucagon-like peptide 1 receptor agonists and to see how
quickly they would progress to insulin requirement follow-
ing the diagnosis of diabetes. Knowing the genetic etiology
here may be helpful in deciding on treatment choice and
advising the patient on the likely disease trajectory.
The past 18 months have seen a number of articles
published that report a large genetic risk for diabetes in
different ethnic groups or isolated populations. For some,
these are population-speciﬁc variants in genes associated
with monogenic diabetes. A recent example is the ﬁnding
of a low-frequency variant in HNF1A in a Latino population
that was associated with a ﬁvefold increased risk for di-
abetes, with the risk variant present at 2.1% in those with
diabetes (12). Similarly, a private G319S variant in HNF1A
in the Oji-Cree tribe was reported in 1999, with homozy-
gous variant carriers having fourfold risk of diabetes (13).
It seems likely that these patient groups will respond well
to sulfonylurea therapy, in keeping with the monogenic
diabetes caused by HNF1A mutations (14), although these
studies have yet to be done. Some large effect variants
have also been described in genes not linked to monogenic
diabetes. The most striking of these is in the Greenlandic
population, where the 3% of the population who are ho-
mozygous for a variant in TBC1D4, which causes muscle
insulin resistance, has a 10-fold increased risk for devel-
oping type 2 diabetes (15). Finally, and more generalizable
across a number of populations, a low-frequency variant
with a minor allele frequency of 1.5% in CCND2 is associated
with a 50% reduction in diabetes risk (16,17). These studies
and the report of ABCC8 variants in the Pima Indian
population (5) reveal that while some diabetes risk vari-
ants of modest effect, such as in TCF7L2 and CCND2, are
seen across populations, it is likely that many more large
effect variants will be identiﬁed by appropriately designed
studies in deﬁned populations. These exciting ﬁndings
and likely future discoveries will increasingly dissect out
subgroups of type 2 diabetes and will increase the likeli-
hood of using genetics to guide a stratiﬁed approach to
diabetes management, but the stratiﬁcation approach used
will need to be population speciﬁc.
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